Forte Biosciences Inc. (FBRX)

Business: Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.

IPO Date: 13-Apr-2017

CEO & Chairman: Dr. Paul A. Wagner Ph.D.

Chief Financial Officer: Mr. Antony A. Riley CPA

Listing: NASDAQ: FBRX

Country: United States

Headquarters: Dallas, TX

Website: https://www.fortebiorx.com

Market cap: $18.75 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.47 Mln

Cash: $40.04 Mln

Total Debt: $0.00 Mln

Insider's Holding: 8.75%

Liquidity: Low

52 Week range: $1.03 - 36.85

Shares outstanding: 14,761,300

7 Years Aggregate:

• CFO: $-154.05 Mln
• EBITDA: $-181.75 Mln
• Net Profit: $-216.68 Mln